CDK4 and cancer: Geoerger et al. evaluated the safety and showed preliminary activity of ribociclib in pretreated neuroblastomas, MRT, and other cancers with documented cyclin D–CDK4/6–INK4–Rb pathways aberrations, including those with SMARCB1 loss [93].